Akshaya Warrier

Akshaya Warrier

Auto-generated profile, based on publicly available information

Akshaya Warrier

Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2019 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
EDEric Devor
Eric Devor
DSDonna Santillan
Donna Santillan
SSSabrina Scroggins
Sabrina Scroggins
AWAkshaya Warrier
Akshaya Warrier
MSMark K. Santillan
Mark K. Santillan
Objective: To identify microRNAs (miRNAs) differentially expressed in plasma exosomes collected in women diagnosed with preeclampsia compared with women with uncomplicated pregnancies. Materials and methods: Exosomes were purified from plasma samples obtained at each trimester from four women subsequently diagnosed with preeclampsia and from five matched healthy controls. RNA was purified from the exosomes, and expression of 368 miRNAs was profiled using A-Set TaqMan low density array (TLDA). Results: One-third of the 368 miRNAs profiled are not expressed in exosomes. Further, those that are not expressed tend to be evolutionarily younger and have a significantly different mature sequence signature than do miRNAs that are expressed in exosomes. Among miRNAs that are expressed in exosomes, a total of eight (miR-134, miR-196b, miR-302c, miR-346, miR-376c, miR-486-3p, miR-590-5p, and miR-618) were found to display statistically significant differential expression between women who developed preeclampsia as compared with those who did not. Moreover, half of these miRNAs (miR-134, miR-376c, miR-486-3p, and miR-590-5p) displayed statistically significant differential expression in the first trimester. Conclusions: Not all miRNAs are expressed in exosomes. Those that tend to be evolutionarily older and have a significantly different mature sequence signature than those that are not. A few exosome-expressed miRNAs do display expression patterns in women subsequently diagnosed with preeclampsia that are significantly different than in women having an uncomplicated and, among these, several appear in the first trimester. These miRNAs are potential early markers of preeclampsia risk.

6 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are lethal, Ras-driven sarcomas that lack effective therapies. We investigated effects of targeting cyclin-dependent kinases 4 and 6 (CDK4/6), MEK, and/or programmed death-ligand 1 (PD-L1) in preclinical MPNST models. Experimental Design: Patient-matched MPNSTs and precursor lesions were examined by FISH, RNA sequencing, IHC, and Connectivity-Map analyses. Antitumor activity of CDK4/6 and MEK inhibitors was measured in MPNST cell lines, patient-derived xenografts (PDX), and de novo mouse MPNSTs, with the latter used to determine anti–PD-L1 response. Results: Patient tumor analyses identified CDK4/6 and MEK as actionable targets for MPNST therapy. Low-dose combinations of CDK4/6 and MEK inhibitors synergistically reactivated the retinoblastoma (RB1) tumor suppressor, induced cell death, and decreased clonogenic survival of MPNST cells. In immune-deficient mice, dual CDK4/6-MEK inhibition slowed tumor growth in 4 of 5 MPNST PDXs. In immunocompetent mice, combination therapy of de novo MPNSTs caused tumor regression, delayed resistant tumor outgrowth, and improved survival relative to monotherapies. Drug-sensitive tumors that regressed contained plasma cells and increased cytotoxic T cells, whereas drug-resistant tumors adopted an immunosuppressive microenvironment with elevated MHC II-low macrophages and increased tumor cell PD-L1 expression. Excitingly, CDK4/6-MEK inhibition sensitized MPNSTs to anti–PD-L1 immune checkpoint blockade (ICB) with some mice showing complete tumor regression. Conclusions: CDK4/6-MEK inhibition induces a novel plasma cell-associated immune response and extended antitumor activity in MPNSTs, which dramatically enhances anti–PD-L1 therapy. These preclinical findings provide strong rationale for clinical translation of CDK4/6-MEK-ICB targeted therapies in MPNST as they may yield sustained antitumor responses and improved patient outcomes.

15 August 2025 in Science Advances
Verified
Journal Article
Open access
GMGavin R. McGivney
Gavin R. McGivney
QBQierra R. Brockman
Qierra R. Brockman
NBNicholas C. Borcherding
Nicholas C. Borcherding
ASAmanda Scherer
Amanda Scherer
ARAdam Rauckhorst
Adam Rauckhorst
RDRebecca Dodd
Rebecca Dodd
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive and chemo-resistant sarcomas with poor survival rates. Loss of CDKN2A or P53 following NF1 disruption is a key event in MPNST development. Here, we used CRISPR-Cas9 somatic tumorigenesis in mice to identify transcriptomic and metabolomic features distinguishing CDKN2A - versus P53 -deleted MPNSTs. Convergent, multiomic analyses revealed that CDKN2A -deleted MPNSTs are especially dependent on the pentose phosphate pathway (PPP) and NADPH metabolism for growth and viability. Disruption of glucose-6-phosphate dehydrogenase (G6PD), the PPP rate-limiting enzyme, slowed CDKN2A -deleted MPNST growth and sensitized MPNSTs to standard-of-care chemotherapy. Knockdown of the redox-regulated transcription factor NRF2 slowed MPNST growth and decreased G6PD transcription. Analysis of patient MPNSTs identified a NRF2 gene signature correlating with tumor transformation. Furthermore, G6PD and NRF2 expression in PanCancer TCGA samples correlates with patient survival. This work identifies NRF2-PPP dependency as a targetable vulnerability in these difficult-to-treat MPNSTs, particularly in the NF1/CDKN2A -deleted majority.

26 September 2021 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Open access
EDEric Devor
Eric Devor
DSDonna Santillan
Donna Santillan
AWAkshaya Warrier
Akshaya Warrier
SSSabrina M. Scroggins
Sabrina M. Scroggins
MSMark K. Santillan
Mark K. Santillan
Examine a mechanism of PLAC1 regulation and its potential role in preeclampsia (PE).Placental tissue samples and detailed clinical information were obtained through the University of Iowa Maternal ...

15 September 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
ASAlexa P. Sheehan
Alexa P. Sheehan
AWAkshaya Warrier
Akshaya Warrier
RDRebecca Dodd
Rebecca Dodd
Summary: Protein arginine methyltransferase 5 inhibitors represent a promising therapeutic approach for multiple cancers, but their clinical development is hindered by toxicity to normal cells. Synthetic lethality approaches using MTAP-cooperative protein arginine methyltransferase 5 inhibitors offer a compelling strategy that selectively targets cancer cells in nerve sheath sarcomas and other MTAP-deleted tumors. See related article by Zhang et al., p. 4779

16 September 2024
Verified
Other
Open access
PDF file
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Supplementary Figure S8. Additional MPNST analyses for CDK4/6-MEK inhibition plus anti-PD-L1 therapy study.